Next Article in Journal
Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study
Next Article in Special Issue
Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens
Previous Article in Journal
Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV
Previous Article in Special Issue
Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessCommunication
Vaccines 2019, 7(1), 4;

Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?

Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
UK Experimental Arthritis Treatment Centre for Children, Department of Women’s and Children’s Health, Institute of Translational Medicine (Child Health), University of Liverpool, Institute in the Park, Alder Hey Children’s NHS Foundation Trust Hospital, Eaton Road, Liverpool L12 2AP, UK
Author to whom correspondence should be addressed.
Received: 31 October 2018 / Revised: 21 December 2018 / Accepted: 2 January 2019 / Published: 3 January 2019
(This article belongs to the Special Issue Vaccines for Pneumococcal Infections)
Full-Text   |   PDF [909 KB, uploaded 8 January 2019]   |  
  |   Review Reports


Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal, Sweden, UK, US) shows limited or no effectiveness of the 13-valent pneumococcal conjugate vaccine against serotype 3 invasive pneumococcal disease and carriage. The serotype 3 capsule has some unique characteristics that may serve to explain this lack of efficacy—capsular polysaccharide is abundantly expressed, leading to a greater thickness of capsule, and free capsular polysaccharide may be released during growth. The serotype 3 component of the Luminex multiplex assay demonstrates inferior inter-laboratory reproducibility than other components and results may not be reliable. This communication outlines this evidence and discusses whether it is necessary to include serotype 3 in the assay in the future. View Full-Text
Keywords: Streptococcus pneumoniae; serotype 3; conjugate vaccine; multiplex; immunoassay Streptococcus pneumoniae; serotype 3; conjugate vaccine; multiplex; immunoassay

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Linley, E.; Bell, A.; Gritzfeld, J.F.; Borrow, R. Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays? Vaccines 2019, 7, 4.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top